Galvão-Moreira and da Cruz summarize the current status of screening for oral cancer and state that “it would probably make sense if biomarkers… could be utilized as complementary tests, instead of primary screening tools, to replace the clinical examination” (1). We agree, and such is the intended use of our panel of biomarkers. Visual inspection of the mouth followed by biopsy remains the basic option for oral cancer screening, especially in countries with high incidence. However, visual screening alone may fail to detect oral squamous cell carcinoma because some patients are unable to open their mouths fully for inspection and because the biopsy is usually limited to a single sample, which could miss the cancer site, especially in patients with multiple types of lesions. The four-protein biomarker panel established in our study (2) is intended as an adjunct to visual screening.